Search / Trial NCT00002819

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Launched by GYNECOLOGIC ONCOLOGY GROUP · May 25, 2004

Trial Information

Current as of January 03, 2025

Terminated

Keywords

Stage Iii Ovarian Epithelial Cancer Recurrent Ovarian Epithelial Cancer Ovarian Undifferentiated Adenocarcinoma Ovarian Mixed Epithelial Carcinoma Ovarian Serous Cystadenocarcinoma Ovarian Mucinous Cystadenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Clear Cell Cystadenocarcinoma Brenner Tumor

ClinConnect Summary

OBJECTIVES: I. Compare progression-free and overall survival of patients with drug-sensitive, low-volume ovarian cancer that is persistent following standard therapy treated with salvage therapy comprising standard-dose paclitaxel and carboplatin vs high-dose carboplatin, mitoxantrone, and cyclophosphamide followed by bone marrow reconstitution. II. Compare the toxic effects of these two salvage regimens. III. Compare selected health-related aspects of quality of life in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified by participating center and di...

Gender

FEMALE

Eligibility criteria

  • DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV ovarian epithelial carcinoma including the following cellular diagnoses: Serous adenocarcinoma Mucinous adenocarcinoma Endometrioid adenocarcinoma Clear cell adenocarcinoma Undifferentiated carcinoma Mixed epithelial carcinoma Transitional cell carcinoma Malignant Brenner's Tumor Stage III (optimal or suboptimal) must be surgically reassessed OR Stage III (suboptimal) or stage IV clinically reassessed after induction chemotherapy For stage III surgical reassessment: No more than 12 weeks between end of chemotherapy and reassessment surgery AND No more than 6 weeks between reassessment surgery and randomization Patients treated on protocol GOG-158 are eligible At least a partial response to chemotherapy as defined as: Microscopic disease documented at reassessment surgery for patients optimally debulked (disease no greater than 1 cm) after primary surgery Suboptimally debulked disease (greater than 1 cm) after primary surgery and 1 of the following: Negative reassessment laparotomy Only microscopic disease at reassessment surgery Gross residual disease no greater than 1 cm at reassessment surgery prior to debulking Clinical complete response to induction chemotherapy including: - suboptimal disease Stage III or IV AND - either an abnormal CT or elevated CA-125 prior to induction chemotherapy and both are within normal limits following induction chemotherapy
  • PATIENT CHARACTERISTICS: Age: Under 66 Performance status: GOG 0 or 1 Hematopoietic: Absolute granulocyte count at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL AST no greater than 3 times normal Renal: Creatinine clearance at least 60 mL/min Cardiovascular: Left ventricular ejection fraction at least 45% by MUGA No congestive heart failure Pulmonary: FEV1 and FVC at least 60% Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No prior malignancy in the past 5 years except adequately treated nonmelanomatous skin cancer, carcinoma in situ of the cervix, or any other cancer whose prior treatment does not contraindicate this study
  • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 4 and no more than 6 prior platinum-based combination chemotherapy courses (i.e., cisplatin or carboplatin) required Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics Other: No prior anthracyclines

Trial Officials

William P. McGuire, MD

Study Chair

Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center

Kenneth B. Miller, MD

Study Chair

Tufts Medical Center Cancer Center

Patrick J. Stiff, MD

Study Chair

Loyola University

Stephen L. Graziano, MD

Study Chair

State University of New York - Upstate Medical University

About Gynecologic Oncology Group

The Gynecologic Oncology Group (GOG) is a leading clinical trial sponsor dedicated to advancing the understanding and treatment of gynecologic cancers. Comprising a network of experts in the field, GOG conducts rigorous, multi-institutional research to evaluate innovative therapeutic strategies and improve patient outcomes. Through its commitment to high-quality clinical trials, the organization aims to enhance the standard of care for women diagnosed with gynecologic malignancies, fostering collaborations with academic institutions and industry partners to translate scientific discoveries into effective treatments. GOG's mission emphasizes patient safety, ethical research practices, and the dissemination of findings to benefit the broader medical community.

Locations

Buffalo, New York, United States

New York, New York, United States

Bronx, New York, United States

Washington, District Of Columbia, United States

Tampa, Florida, United States

Chicago, Illinois, United States

Iowa City, Iowa, United States

Worcester, Massachusetts, United States

Minneapolis, Minnesota, United States

Chapel Hill, North Carolina, United States

Durham, North Carolina, United States

Winston Salem, North Carolina, United States

Charleston, South Carolina, United States

Chicago, Illinois, United States

Miami, Florida, United States

Providence, Rhode Island, United States

Burlington, Vermont, United States

Las Vegas, Nevada, United States

La Jolla, California, United States

San Francisco, California, United States

Wilmington, Delaware, United States

Miami Beach, Florida, United States

Baltimore, Maryland, United States

Columbia, Missouri, United States

Saint Louis, Missouri, United States

Lebanon, New Hampshire, United States

Manhasset, New York, United States

Syracuse, New York, United States

Winston Salem, North Carolina, United States

Memphis, Tennessee, United States

Richmond, Virginia, United States

New York, New York, United States

Peoria, Illinois, United States

Urbana, Illinois, United States

Des Moines, Iowa, United States

Boston, Massachusetts, United States

Boston, Massachusetts, United States

Kalamazoo, Michigan, United States

Saint Louis Park, Minnesota, United States

Hackensack, New Jersey, United States

Philadelphia, Pennsylvania, United States

Nashville, Tennessee, United States

New York, New York, United States

Fargo, North Dakota, United States

Birmingham, Alabama, United States

White River Junction, Vermont, United States

Marshfield, Wisconsin, United States

Chicago, Illinois, United States

Boston, Massachusetts, United States

Manhasset, New York, United States

Chicago, Illinois, United States

San Francisco, California, United States

Syracuse, New York, United States

Memphis, Tennessee, United States

Richmond, Virginia, United States

Chicago, Illinois, United States

Togus, Maine, United States

Minneapolis, Minnesota, United States

Columbia, Missouri, United States

Omaha, Nebraska, United States

Buffalo, New York, United States

Syracuse, New York, United States

Durham, North Carolina, United States

Nashville, Tennessee, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials